Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2885 - Cancer-associated thrombosis in patients with pancreatic cancer and its correlation with plasma tissue factor level: A Japanese prospective cohort study


29 Sep 2019


Poster Display session 2


Tumour Site

Pancreatic Adenocarcinoma


Satoshi Kobayashi


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


S. Kobayashi1, S. Koizume2, Y. Miyagi2, M. Ueno1, M. Morimoto3

Author affiliations

  • 1 Gastroenterology, Kanagawa Cancer Center, 2418515 - Yokohama/JP
  • 2 Molecular Pathology & Genetics Division, Kanagawa Cancer Center Research Institute, 2418515 - Yokohama/JP
  • 3 Department Of Gastroenterology, Kanagawa Cancer Center, 2418515 - Yokohama/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2885


Cancer-associated thrombosis (CAT) is a well–known complication of cancer, especially pancreatic cancer. One possible cause of CAT is secretion of tissue factor (TF)-positive extracellular vesicles from cancer cells. The previous cohort of Western countries showed that patients (pts) with a high level of TF tended to develop CAT with 20–40% incidence in pancreatic cancer. This prospective cohort study aimed to assess the efficacy of TF level for predicting the incidence of CAT in Japanese pts with pancreatic cancer.


We registered consented 197 pts from June 2013 to November 2016, who had pathologically confirmed pancreatic cancer and no history of treatment for the current disease. Plasma samples were collected from pts at the time of registration, 3, 6, and 12 months after. The TF level was evaluated using the Quantikine® ELISA kit (R&D systems) as we found that TF levels in multiple cancer cell lines evaluated using this kit correlated well with those analyzed by western blotting experiments. We estimated the positive (PPV) and negative predictive values (NPV) for the incidence of CAT by using obtained plasma TF levels (cutoff value: 100 pg/ml) and D-dimer levels (cutoff value: 1.2 μg/ml).


Of all the patients, 189 patients were with unresectable disease. The median of the initial level of TF for these pts was 47.8 pg/ml (range: 0.0—318.7). The incidence of CAT was observed in 13 pts (6.6%) at the median follow-up time of 325 days. The median TF level at the time of registration was 148.5 pg/ml in CAT+ group and 53.5 pg/ml in CAT- group with a p–value of < 0.0001. PPV and NPV estimated by TF levels at the time of registration were 23.1% and 94.6%, and by the D-dimer levels were 7.2% and 92.4%, respectively. In pts with a D-dimer level >1.2 µg/ml, NPV by TF < 100 pg/ml was 95%. Similar results were obtained when TF levels of 3 months before the onset of CAT were used.


Present study revealed that the incidence of CAT in Japanese pts was lower than that of Western countries. It was also found that TF levels alone could not predict CAT observed in Japanese pts with pancreatic cancer: however, TF levels were found to contribute to high NPV even in pts with a high level of D–dimer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.